US Blood Cancer Drug Market Sales Revenue Clinical Trials Pipeline Report 2015

Pharmaceutical companies have identified the opportunities to generate significant revenues from blood cancer segment in US. Escalating blood cancer incidences, high unmet medical necessities and demand for better therapeutics are some major factors behind growth of US blood cancer market segment. Higher investments have been made by pharmaceutical companies in order to come forth with better therapeutics for generating significant revenues. As a result, numerous therapeutic have been introduced in US market for the successful treatment of blood cancer. Several innovative therapeutics are at different stages of clinical trials which would be introduced in coming years.

Download Report:

https://www.kuickresearch.com/report-US-Blood-Cancer-Drug-Market-&-Pipeline-Analysis-2015.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"US Blood Cancer Drug Market & Pipeline Analysis 2015" Table of Contents

1. US Blood Cancer Incidence & Prevalence
1.1 Leukemia: Cancer of White Blood Cells (WBC)
1.1.1 Acute Lymphocytic Leukemia (ALL)
1.1.2 Acute Myeloid Leukemia (AML)
1.1.3 Chronic Lymphocytic Leukemia (CLL)
1.1.4 Chronic Myeloid Leukemia (CML)
1.2 Lymphoma: Cancer of Lymphatic System
1.2.1 Hodgkin Lymphoma
1.2.2 Non-Hodgkin Lymphoma (NHL)
1.3 Myeloma

2. US Blood Cancer Drug Market Overview
2.1 Current Market Scenario
2.2 US Blood Cancer Drug Clinical Pipeline Overview

3. US Blood Cancer Drug Market Dynamics
3.1 Favorable Market Parameters
3.2 Commercialization Challenges

4. US Blood Cancer Drug Market Future Prospects

5. Mechanism of Blood Cancer Therapeutics

6. Leukemia Drug Clinical Pipeline by Company & Phase
6.1 Research till Registered
6.2 Discontinued & Suspended Leukemia Drug Clinical Insight

7. Marketed Leukemia Drug Clinical Insight
7.1 Alemtuzumab (Campath®)
7.2 Arsenic Trioxide (Trisenox®)
7.3 Bosutinib (Bosulif®)
7.4 Clofarabine
7.5 Crisantaspase (Erwinaze®)
7.6 Dasatinib (Sprycel®)
7.7 Fludarabine (Fludara®)
7.8 Idarubicin (Idamycin®)
7.9 Imatinib (Gleevec®)
7.10 Irinotecan
7.11 Mercaptopurine Oral Suspension (Purixan™)
7.12 Mitoxantrone (Novantrone®)
7.13 Nilotinib (Tasigna®)
7.14 Obinutuzumab (Gazyva®)
7.15 Ofatumumab (Arzerra®)
7.16 Omacetaxine Mepesuccinate (Synribo®)
7.17 Pegaspargase (Oncaspar®)
7.18 Pentostatin (Nipent®)
7.19 Ponatinib (Iclusig®)
7.20 Sargramostim (Leukine®)
7.21 Tretinoin
7.22 Vincristine Liposomal - Spectrum Pharmaceuticals (Marqibo®)

8. Lymphoma Drug Clinical Pipeline by Company & Phase
8.1 Research till Registered
8.2 Discontinued & Suspended Lymphoma Drug Clinical Insight

9. Marketed Lymphoma Drug Clinical Insight
9.1 Belinostat (Beleodaq®)
9.2 Bexarotene Oral (Targretin®)
9.3 Bexarotene Topical (Targretin®)
9.4 Brentuximab Vedotin (Adcetris®)
9.5 Chlormethine (Valchlor™)
9.6 Denileukin Diftitox (ONTAK®)
9.7 Ibritumomab Tiuxetan (Zevalin®)
9.8 Interferon Alpha-2b (Intron® A)
9.9 Pralatrexate (Folotyn®)
9.10 Romidepsin (Istodax®)
9.11 Vorinostat (Zolinza®)


10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase
10.1 Research till Preregistration
10.2 Discontinued & No Development Reported in Multiple Myeloma Drug Clinical Insight

11. Marketed Multiple Myeloma Drug Clinical Insight
11.1 Carfilzomib (Kyprolis®)
11.2 Doxorubicin Liposomal – ALZA
11.3 Pomalidomide (Pomalyst®)
11.4 Thalidomide (Thalomid®)
11.5 Zoledronic Acid (Zometa®)

12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase
12.1 Research till Preregistration
12.2 Discontinued & Suspended Multiple Blood Cancer Drug Clinical Insight

13. Marketed Multiple Blood Cancer Drug Clinical Insight
13.1 Azacitidine (Vidaza®)
13.2 Bendamustine (Treanda®)
13.3 Bortezomib (Velcade®)
13.4 Cladribine (Leustatin®)
13.5 Decitabine (Dacogen®)
13.6 Ibrutinib (Imbruvica®)
13.7 Idelalisib
13.8 Lenalidomide (Revlimid®)
13.9 Nelarabine (Arranon®)
13.10 Rituximab (Rituxan®)

14. Competitive Landscape
14.1 Actelion Pharmaceuticals
14.2 Amgen
14.3 ARIAD Pharmaceuticals
14.4 Astellas Pharma
14.5 Baxter BioScience
14.6 Bayer HealthCare Pharmaceuticals Inc.
14.7 Biogen Idec
14.8 Bristol-Myers Squibb
14.9 CASI Pharmaceuticals
14.10 Celera Genomics Group
14.11 Celgene Corporation
14.12 Eisai
14.13 Genmab
14.14 Gilead Sciences
14.15 GlaxoSmithKline
14.16 Hospira
14.17 Johnson & Johnson
14.18 Millennium Pharmaceuticals
14.19 Nova Laboratories
14.20 Novartis
14.21 Onxeo SA
14.22 Onyx Pharmaceuticals
14.23 Otsuka Pharmaceutical
14.24 Pfizer
14.25 Roche
14.26 Scripps Clinic
14.27 Seattle Genetics
14.28 SRI International
14.29 Southern Research Institute
14.30 Tekmira Pharmaceuticals Corporation
14.31 Teva Pharmaceutical Industries
14.32 Yakult Honsha

Figure 1-1: Main Types of Blood Cancer
Figure 1-2: Percentage of Leukemia in New Cancer Cases, 2015
Figure 1-3: Percentage of Leukemia in all Cancer Related Deaths, 2015
Figure 1-4: Leukemia Estimated Cases, 2013-2015
Figure 1-5: Leukemia Estimated New Cases in Males, 2013-2015
Figure 1-6: Leukemia Estimated New Cases in Females, 2013-2015
Figure 1-7: Leukemia Estimated Deaths, 2013-2015
Figure 1-8: Leukemia Estimated Deaths in Males, 2013-3015
Figure 1-9: Leukemia Estimated Deaths in Females, 2013-2015
Figure 1-10: Percentage of Acute Lymphocytic Leukemia in Cancer Related Deaths, 2015
Figure 1-11: Percentage of Acute Lymphocytic Leukemia in New Cancer Cases, 2015
Figure 1-12: Acute Lymphocytic Leukemia Estimated New Cases, 2013-2015
Figure 1-13: Acute Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015
Figure 1-14: Acute Lymphocytic Leukemia Estimated New Cases in Female, 2013-2015
Figure 1-15: Acute Lymphocytic Leukemia Estimated Deaths, 2013-2015
Figure 1-16: Acute Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015
Figure 1-17: Acute Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015
Figure 1-18: Acute Myeloid Leukemia Estimated New Cases, 2013-2015
Figure 1-19: Acute Myeloid Leukemia Estimated New Cases in Males, 2013-2015
Figure 1-20: Acute Myeloid Leukemia Estimated New Cases in Females, 2013-2015
Figure 1-21: Percentage of Acute Myeloid Leukemia in New Cancer Cases, 2015
Figure 1-22: Percentage of Acute Myeloid Leukemia in all Cancer Deaths, 2015
Figure 1-23: Acute Myeloid Leukemia Estimated Deaths, 2013-2015
Figure 1-24: Acute Myeloid Leukemia Estimated Deaths in Male, 2013-2015
Figure 1-25: Acute Myeloid Leukemia Estimated Deaths in Female, 2013-2015
Figure 1-26: Chronic Lymphocytic Leukemia Estimated New Cases, 2013-2015
Figure 1-27: Chronic Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015
Figure 1-28: Chronic Lymphocytic Leukemia Estimated New Cases in Females, 2013-2015
Figure 1-29: Chronic Lymphocytic Leukemia Estimated Deaths, 2013-2015
Figure 1-30: Percentage of Chronic Lymphocytic Leukemia in New Cancer Cases, 2015
Figure 1-31: Percentage of Chronic Lymphocytic Leukemia in all Cancer Related Deaths, 2015
Figure 1-32: Chronic Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015
Figure 1-33: Chronic Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015
Figure 1-34: Percentage of Chronic Myeloid Leukemia in New Cancer Cases, 2015
Figure 1-35: Percentage of Chronic Myeloid Leukemia in all Cancer Related Deaths, 2015
Figure 1-36: Categories of Chronic Myeloid Leukemia (CML)
Figure 1-37: Chronic Myeloid Leukemia Estimated New Cases, 2013-2015
Figure 1-38: Estimated New Cases of Chronic Myeloid Leukemia in Males, 2013-2015
Figure 1-39: Estimated New Cases of Chronic Myeloid Leukemia in Females, 2013-2015
Figure 1-40: Estimated Deaths due to Chronic Myeloid Leukemia, 2013-2015
Figure 1-41: Estimated Deaths due to Chronic Myeloid Leukemia in Male, 2013-2015
Figure 1-42: Estimated Deaths due to Chronic Myeloid Leukemia in Female, 2013-2015
Figure 1-43: Types of Lymphoma
Figure 1-44: Identification of Different Types of Lymphomas
Figure 1-45: Lymphoma Estimated New Cases, 2013-2015
Figure 1-46: Estimated New Cases of Lymphoma in Males, 2013-2015
Figure 1-47: Estimated New Cases of Lymphoma in Females, 2013-2015
Figure 1-48: Estimated Lymphoma Deaths, 2013-2015
Figure 1-49: Lymphoma Estimated Deaths in Males, 2013-2015
Figure 1-50: Lymphoma Estimated Deaths in Females, 2013-2015
Figure 1-51: Percentage of Hodgkin Lymphoma in New Cancer Cases, 2015
Figure 1-52: Percentage of Hodgkin Lymphoma in all Cancer Related Deaths, 2015
Figure 1-53: Estimated New Cases of Hodgkin Lymphoma, 2013-2015
Figure 1-54: Estimated New Cases of Hodgkin Lymphoma in Male, 2013-2015
Figure 1-55: Estimated New Cases of Hodgkin Lymphoma in Females, 2013-2015
Figure 1-56: Hodgkin Lymphoma Estimated Deaths, 2013-2015
Figure 1-57: Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015
Figure 1-58: Hodgkin Lymphoma Estimated Deaths in Female, 2013-2015
Figure 1-59: Percentage of Non-Hodgkin Lymphoma (NHL) in New Cancer Cases, 2015
Figure 1-60: Percentage of Non-Hodgkin Lymphoma in all Cancer Related Deaths, 2015
Figure 1-61: Non-Hodgkin Lymphoma Estimated New Cases, 2013-2015
Figure 1-62: Non-Hodgkin Lymphoma Estimated New Cases in Male, 2013-2015
Figure 1-63: Non-Hodgkin Lymphoma Estimated New Cases in Female, 2013-2015
Figure 1-64: Non-Hodgkin Lymphoma Estimated Deaths, 2013-2015
Figure 1-65: Non-Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015
Figure 1-66: Non-Hodgkin Lymphoma Estimated Deaths in Females, 2015- 2013
Figure 1-67: Percentage of Myeloma in New Cancer Cases, 2015
Figure 1-68: Myeloma Estimated New Cases, 2013-2015
Figure 1-69: Myeloma Estimated New Cases in Males, 2013-2105
Figure 1-70: Myeloma Estimated New Cases in Females, 2013-2015
Figure 1-71: Percentage of Myeloma in all Cancer Related Deaths, 2015
Figure 1-72: Myeloma Estimated Deaths, 2013-2015
Figure 1-73: Myeloma Estimated Deaths in Males, 213-2015
Figure 1-74: Myeloma Estimated Deaths in Females, 2013-2015
Figure 2-1: Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-2: Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-3: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-4: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-5: Discontinued Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-6: Discontinued Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-7: Suspended Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-8: Suspended Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-9: Leukemia Drug Pipeline Overview by Phase (%), 2015
Figure 2-10: Leukemia Drug Pipeline Overview by Phase (Number), 2015
Figure 2-11: No Development Reported Leukemia Drug Pipeline Overview by Phase (%), 2015
Figure 2-12: No Development Reported Leukemia Drug Pipeline Overview by Phase (Number), 2015
Figure 2-13: Discontinued Leukemia Drug Pipeline Overview by Phase (%), 2015
Figure 2-14: Discontinued Leukemia Drug Pipeline Overview by Phase (Number), 2015
Figure 2-15: Suspended Leukemia Drug Pipeline Overview by Phase (%), 2015
Figure 2-16: Suspended Leukemia Drug Pipeline Overview by Phase (Number), 2015
Figure 2-17: Lymphoma Drug Pipeline Overview by Phase (%), 2015
Figure 2-18: Lymphoma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-19: No Development Reported Lymphoma Drug Pipeline Overview by Phase (%), 2015
Figure 2-20: No Development Reported Lymphoma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-21: Discontinued Lymphoma Drug Pipeline Overview by Phase (%), 2015
Figure 2-22: Discontinued Lymphoma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-23: Suspended Lymphoma Drug Pipeline Overview by Phase (%), 2015
Figure 2-24: Suspended Lymphoma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-25: Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
Figure 2-26: Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-27: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
Figure 2-28: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-29: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
Figure 2-30: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-31: Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-32: Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-33: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-34: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-35: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-36: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-37: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-38: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 3-1: US Blood Cancer Drug Market Favorable Parameters
Figure 3-2: US Blood Cancer Drug Market Commercialization Challenges
Figure 5-1: Mechanism of Idelalisib
Figure 5-2: Mechanism of Imatinib
Figure 5-3: Mechanism of Rituximab
Figure 5-4: Mechanism of Doxorubicin
Figure 5-5: Mechanism of Carfilzomib
Figure 14-1: Actelion Pharmaceuticals Clinical Pipeline
Figure 14-2: Amgen Clinical Pipeline
Figure 14-3: ARIAD Clinical Pipeline
Figure 14-4: Casi Pharmaceutical Clinical Pipeline
Figure 14-5: Celgene Clinical Pipeline
Figure 14-6: Gilead Sciences Clinical Pipeline
Figure 14-7: GalaxoSmithKline Clinical Pipeline
Figure 14-8: Millennium Pharmaceuticals Clinical Pipeline
Figure 14-9: Novartis Clinical Pipeline
Figure 14-10: Onxeo SA Clinical Pipeline
Figure 14-11: Roche Clinical Pipeline
Figure 14-12: Tekmira Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.